Biomedical Reform Legislation Draft Could Be Released By January
This article was originally published in The Pink Sheet Daily
At the final roundtable for the 21st Century Cures initiative in Washington, Chairman Upton promises swift action, and urges stakeholders to submit their ideas “as soon as possible.”
You may also be interested in...
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
Pink Sheet Podcast: FDA User Fee Bill Mark-Up, Postmarket Quality Requirements, Fewer Adcom Meetings
Pink Sheet reporter and editors discuss the first mark-up of the House FDA user fee bill, the likelihood of more postmarketing quality requirements for drug manufacturers, and the significance of the shrinking number of FDA advisory committee meetings.